As discussed above, the evidence for GLP‐1 RAs, dual GLP‐1/GIP RAs, and other incretin‐based therapies in HFrEF remains limited and inconclusive, with concerns about potential adverse effects such as arrhythmias and worsening HF. This evidence concerns the gene GLP1R and cardiac arrhythmia.